# Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

> **NCT04226170** · PHASE2 · TERMINATED · sponsor: **DAS-MG, Inc** · enrollment: 2 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** DAS-001

## Key facts

- **NCT ID:** NCT04226170
- **Lead sponsor:** DAS-MG, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-08
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** lack of enrollment
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226170, "Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04226170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*